Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Avion Medical Skin Centres to Offer Innovative Treatment for Non-Melanoma Skin Cancer Patients
Details : Traditional treatment methods typically involve surgery, which may have a risk of scarring or loss of function, treatment with Rhenium-SCT (Rhenium-188) employs a non-invasive superficial application of a paste containing ß-emitting particles directly t...
Product Name : Rhenium-SCT
Product Type : Small molecule
Upfront Cash : Undisclosed
June 23, 2022
Lead Product(s) : Conjugated Estrogens
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved
Recipient : Aspen Pharmacare Holdings
Deal Size : Undisclosed
Deal Type : Partnership
Aspen Concludes Strategic Partnership with U.S-Based Avion Pharmaceuticals
Details : Avion Pharmaceuticals gets exclusive rights to relaunch Cenestin® in the USA. Cenestin® is the only plant-derived mixture of nine conjugated estrogens indicated for treatment of moderate to severe symptoms of vasomotor, and vulvar and vaginal atrophy d...
Product Name : Cenestin
Product Type : Small molecule
Upfront Cash : Undisclosed
November 12, 2020
Lead Product(s) : Conjugated Estrogens
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved
Recipient : Aspen Pharmacare Holdings
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Colchicine
Therapeutic Area : Rheumatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Gloperba (colchicine oral solution) inhibits the Beta tubulin polymerisation, which is indicated for the prophylaxis of gout flares in adults patients.
Product Name : Gloperba
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
February 27, 2020
Lead Product(s) : Colchicine
Therapeutic Area : Rheumatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable